Effect of selective androgen receptor modulator RAD140 on prostate and testosterone levels in Wistar strain rats with bilateral orchidectomy
Abstract
BACKGROUND Selective androgen receptor modulators (SARMs) have been investigated as a potential treatment for hypogonadism, a condition characterized by low testosterone levels in men. The idea is to provide therapeutic benefits similar to traditional testosterone replacement therapy. However, research in this area is still in its early stages, and more extensive studies are needed to establish the efficacy of SARM. This study aimed to determine the impact of SARM RAD140 on testosterone levels, fibromuscular stroma, and prostate mass in rats undergoing bilateral orchidectomy.
METHODS This was an in vivo study using posttest-only control group design in rats (Rattus norvegicus). The positive and negative control groups consisted of rats with and without bilateral orchidectomy, respectively. The treatment groups were rats given SARM RAD140 with and without orchidectomy. Testosterone levels, histopathology, and prostate mass were examined at the end of week 6, and the quantitative data were analyzed using one-way ANOVA.
RESULTS This study found no difference in prostate mass (0.598 [0.05] g versus 0.590 [0.07] g, p = 0.984), fibromuscular stroma ratio (0.483 [0.094] versus 0.463 [0.057], p = 0.984), and testosterone level (0.006 [0.005] ng/dl versus 0.014 [0.004] ng/dl, p = 0.098) compared to positive control with orchidectomy and SARM RAD140 administration 6 weeks after treatment.
CONCLUSIONS There were no differences in testosterone levels, prostate mass, or the ratio of fibromuscular stroma to epithelium area in rats undergoing bilateral orchidectomy and placebo surgery with the administration of SARM RAD140.
Downloads
References
Salonia A, Bettocchi C, Boeri L, Capogrosso P, Carvalho J, Cilesiz NC, et al. European Association of Urology guidelines on sexual and reproductive health-2021 update: male sexual dysfunction. Eur Urol. 2021;80(3):333−57. https://doi.org/10.1016/j.eururo.2021.06.007
Christiansen AR, Lipshultz LI, Hotaling JM, Pastuszak AW. Selective androgen receptor modulators: the future of androgen therapy? Transl Androl Urol. 2020;9(Suppl 2):S135−48. https://doi.org/10.21037/tau.2019.11.02
Itty S, Getzenberg RH. How do we define "castration" in men on androgen deprivation therapy? Asian J Androl. 2020;22(5):441−6. https://doi.org/10.4103/aja.aja_139_19
Yeo S, Holl K, Peñaherrera N, Wissinger U, Anstee K, Wyn R. Burden of male hypogonadism and major comorbidities, and the clinical, economic, and humanistic benefits of testosterone therapy: a narrative review. Clinicoecon Outcomes Res. 2021;13:31−8. https://doi.org/10.2147/CEOR.S285434
Zitzmann M. Testosterone, mood, behaviour and quality of life. Andrology. 2020;8(6):1598−605. https://doi.org/10.1111/andr.12867
Levy JA, Burnett AL, Dobs AS. Testosterone treatment and the risk of prostate adverse events. Endocrinol Metab Clin North Am. 2022;51(1):123−31. https://doi.org/10.1016/j.ecl.2021.11.011
Barbonetti A, D'Andrea S, Francavilla S. Testosterone replacement therapy. Andrology. 2020;8(6):1551−66. https://doi.org/10.1111/andr.12774
Efimenko IV, Chertman W, Masterson TA, Dubin JM, Ramasamy R. Analysis of the growing public interest in selective androgen receptor modulators. Andrologia. 2021;53(11):e14238. https://doi.org/10.1111/and.14238
Gorczyca D, Kwiatkowska D. Duality nature of selective androgen receptor modulators and specific steroids substance. Disaster Emerg Med J. 2019;4(2):60-2. https://doi.org/10.5603/DEMJ.2019.0012
Felix-Patrício B, Miranda AF, Medeiros JL Jr, Gallo CB, Gregório BM, Souza DB, et al. The prostate after castration and hormone replacement in a rat model: structural and ultrastructural analysis. Int Braz J Urol. 2017;43(5):957−65. https://doi.org/10.1590/s1677-5538.ibju.2016.0484
Christiansen AR, Lipshultz LI, Hotaling JM, Pastuszak AW. Selective androgen receptor modulators: the future of androgen therapy? Transl Androl Urol. 2020;9(Suppl 2):S135−48. https://doi.org/10.21037/tau.2019.11.02
Nejishima H, Yamamoto N, Suzuki M, Furuya K, Nagata N, Yamada S. Anti-androgenic effects of S-40542, a novel non-steroidal selective androgen receptor modulator (SARM) for the treatment of benign prostatic hyperplasia. Prostate. 2012;72(14):1580−7. https://doi.org/10.1002/pros.22511
Wagener F, Euler L, Görgens C, Guddat S, Thevis M. Human in vivo metabolism and elimination behavior of micro-dosed selective androgen receptor modulator RAD140 for doping control purposes. Metabolites. 2022;12(7):666. https://doi.org/10.3390/metabo12070666
Fonseca GW, Dworatzek E, Ebner N, Von Haehling S. Selective androgen receptor modulators (SARMs) as pharmacological treatment for muscle wasting in ongoing clinical trials. Expert Opin Investig Drugs. 2020;29(8):881−91. https://doi.org/10.1080/13543784.2020.1777275
Kajiwara S, Ishii K, Sasaki T, Kato M, Nishikawa K, Kanda H, et al. Castration-induced stromal remodeling disrupts the reconstituted prostate epithelial structure. Lab Invest. 2020;100(5):670-81. https://doi.org/10.1038/s41374-019-0352-4
Zhang J, Zhang M, Tang J, Yin G, Long Z, He L, et al. Animal models of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 2021;24(1):49−57. https://doi.org/10.1038/s41391-020-00277-1
Vickman RE, Franco OE, Moline DC, Vander Griend DJ, Thumbikat P, Hayward SW. The role of the androgen receptor in prostate development and benign prostatic hyperplasia: a review. Asian J Urol. 2020;7(3):191−202. https://doi.org/10.1016/j.ajur.2019.10.003
Unwalla R, Mousseau JJ, Fadeyi OO, Choi C, Parris K, Hu B, et al. Structure-based approach to identify 5-[4-hydroxyphenyl]pyrrole-2-carbonitrile derivatives as potent and tissue selective androgen receptor modulators. J Med Chem. 2017;60(14):6451−7. https://doi.org/10.1021/acs.jmedchem.7b00373
Miller CP, Shomali M, Lyttle CR, O'Dea LS, Herendeen H, Gallacher K, et al. Design, synthesis, and preclinical characterization of the selective androgen receptor modulator (SARM) RAD140. ACS Med Chem Lett. 2010;2(2):124−9. https://doi.org/10.1021/ml1002508
Al-Shahat AR, Shaikh MA, Elmansy RA, Shehzad K, Kaimkhani ZA. Prostatic assessment in rats after bilateral orchidectomy and calcitonin treatment. Endocr Regul. 2011;45(1):29−36.
Angrimani DS, Francischini MC, Brito MM, Vannucchi CI. Prostatic hyperplasia: vascularization, hemodynamic and hormonal analysis of dogs treated with finasteride or orchiectomy. PLoS One. 2020;15(6):e0234714. https://doi.org/10.1371/journal.pone.0234714
Jayaraman A, Christensen A, Moser VA, Vest RS, Miller CP, Hattersley G, et al. Selective androgen receptor modulator RAD140 is neuroprotective in cultured neurons and kainate-lesioned male rats. Endocrinology. 2014;155(4):1398−406. https://doi.org/10.1210/en.2013-1725
Solomon ZJ, Mirabal JR, Mazur DJ, Kohn TP, Lipshultz LI, Pastuszak AW. Selective androgen receptor modulators: current knowledge and clinical applications. Sex Med Rev. 2019;7(1):84−94. https://doi.org/10.1016/j.sxmr.2018.09.006
Copyright (c) 2024 Taufiq Nur Budaya, Pradana Nurhadi, Kenty Wantri Anita, Prasetyo Nugroho, Fauzan Kurniawan Dhani
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with Medical Journal of Indonesia agree to the following terms:
- Authors retain copyright and grant Medical Journal of Indonesia right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial License that allows others to remix, adapt, build upon the work non-commercially with an acknowledgment of the work’s authorship and initial publication in Medical Journal of Indonesia.
- Authors are permitted to copy and redistribute the journal's published version of the work non-commercially (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in Medical Journal of Indonesia.
